Roche announced its investigational antibody gantenerumab failed to meet the primary endpoints in GRADUATE I and II – two Phase III studies in Alzheimer’s disease.
https://www.pharmalive.com/wp-content/uploads/2021/09/Roche-Bolsters-Diagnostics-Division-with-Acquisition-of-Longtime-Partner-BioSpace-9-9-21.jpeg350625BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2022-11-14 09:18:452022-11-14 09:18:45Biogen-Lilly solidly in the lead after Roche’s Alzheimer’s Drug misses in Phase III
